Activities of erythropoietin on tumors: An immunological perspective

European Journal of Immunology

Volumn 37, Issue 6, 2007, Pages 1427-1430

  Ghezzi, Pietro ^a   Mengozzi, Manuela ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Cytokines; Erythropoietin; Tumor immunology

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; TETANUS TOXOID; TUMOR NECROSIS FACTOR;

ANEMIA; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; B LYMPHOCYTE ACTIVATION; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG INDICATION; ERYTHROPOIESIS; GROWTH CURVE; HUMAN; IMMUNE SYSTEM; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MULTIPLE MYELOMA; NEUROPATHY; NEUROPROTECTION; NONHUMAN; NOTE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; STROKE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODY FORMATION; ERYTHROPOIETIN; HUMANS; LYMPHOCYTES; MICE; MULTIPLE MYELOMA; NEOPLASMS;

EID: 34250634027     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200737401     Document Type: Note

References (20)

1. Wilson, J., Yao, G. L., Raftery, J., Bohlius, J., Brunskill, S., Sandercock J., Bayliss, S. et al., A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol. Assess. 2007. 11: 1-220.
2. Brines, M. and Cerami, A., Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci. 2005. 6: 484-494.
3. Bianchi, R., Brines, M., Lauria, G., Savino, C., Gilardini, A., Nicolini G., Rodriguez-Menendez, V. et al., Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin. Cancer Res. 2006. 12: 2607-2612.
4. Hamed, S., Barshack, L, Luboshits, G., Wexler, D., Deutsch, V., Keren, G. and George, J., Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur. Hear. J. 2006. 27: 1876-1883.
5. Leist, M., Ghezzi, P., Grasso, G., Bianchi, R., Villa, P., Fratelli, M., Savino, C. et al., Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic. Science 2004. 305: 239-242.
6. Crawford, J., Erythropoietin: High profile, high scrutiny. J. Clin. Oncol. 2007. 25: 1021-1023.
7. Katz, O., Gil, L., Liftshitz, L., Prutchi-Sagiv, S., Gassmann, M., Mittelman, M. and Neumann, D., Erythropoietin Enhances Immune Responses in Mice. Eur. J. Immunol. 2007. 37: DOI 10.1002/ eji.200637025
8. Mittelman, M., Zeidman, A., Kanter, P., Katz, O., Oster, H., Rund, D. and Neumann, D., Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies. Eur J. Haematol. 2004. 72: 155-165.
9. Baz, R., Walker, E., Choueiri, T. K., Abou Jawde, R., Brand, C., McGowan B., Yiannaki, E. et al., Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol. 2007. 117: 162-167.
10. Mittelman, M., Neumann, D., Peled, A., Kanter, P. and Haran-Ghera, N., Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc. Natl. Acad. Sci. USA 2001. 98: 5181-5186.
11. Prutchi-Sagiv, S., Golishevsky, N., Oster, H. S., Katz, O., Cohen, A., Naparstek, E., Neumann, D. and Mittelman, M., Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease? Br. J. Haematol. 2006. 135: 660-672.
12. Bryl, E., Mysliwska, J., Debska-Slizien, A., Trzonkowski, P., Rachon, D., Bullo, B., Zdrojewski, Z. et al., Recombinant human erythropoietin stimulates production of interleukin 2 by whole blood cell cultures of hemodialysis patients. Artif. Organs 1999. 23: 809-816.
13. Trzonkowski, P., Debska-Slizien, A., Szmit, E., Mysliwska, J., Szymanska, K., Hak, L., Mysliwski, A. and Rutkowski, B., Long-term therapy with recombinant human erythropoietin increases CD8+ T cell apoptosis in haemodialysis patients. Nephrol. Dial. Transplant. 2005. 20: 367-376.
14. Sennesael, J. J., Van der Niepen, P. and Verbeelen, D. L., Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int. 1991. 40: 121-128.
15. Schaefer, R. M., Paczek, L., Berthold, G., Gilge, U. and Heidland, A., Improved immunoglobulin production in dialysis patients treated with recombinant erythropoietin. Int. J. Artif. Organs 1992. 15: 204-208.
16. Roman, R. M., Lobo, P. I., Taylor, R. P., Goodkin, D. A., LaBrecque, J., Powers, K. L. and Bolton, W. K., Prospective study of the immune effects of normalizing the hemoglobin concentration in hemodialysis patients who receive recombinant human erythropoietin. J. Am. Soc. Nephrol. 2004. 15: 1339-1346.
17. Yorioka, N., Hamaguchi, N., Takasugi, N., Shigemoto, K., Harada, S., Fujiwara, K., Ishida, A. et al., Effect of recombinant human erythropoietin administration on immunological indices in patients undergoing chronic hemodialysis. Nippon. Jinzo Gakkai. Shi. 1993. 35: 981-988.
18. Hannula, P., Ala-Houhala, I., Saha, H., Lagerstedt, A., Parviainen, T., Pastemack, A. and Antonen, J., Effects of erythropoietin treatment on cell-mediated immune responses in predialysis patients. Scand. J. Urol. Nephrol. 2006. 40: 241-246.
19. Kimata, H., Yoshida, A., Ishioka, C., Masuda, S., Sasaki, R. and Mikawa, H., Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum-free medium. Clin. Exp. Immunol. 1991. 85: 151-156.
20. Haroon, Z. A., Amin, K., Jiang, X. and Arcasoy, M. O., A novel role for erythropoietin during fibrin-induced wound-healing response. Am. J. Pathol. 2003. 163: 993-1000.